NC
CLCD

Nexthera Capital’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Nexthera Capital’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100,000
Closed -$3.81M – 53
2016
Q3 		$3.81M Buy
+100,000
New +$1.48M 2.34% 14

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Nexthera Capital's CLCD Position: Q4 2016 in Review

Nexthera Capital sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2016, closing a stake of 100,000 shares — an estimated $3.81M sold.

Nexthera Capital first reported a position in CLCD in Q3 2016 and held it in 1 quarter. The position peaked at $3.81M in Q3 2016. 76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

  • Nexthera Capital reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Nexthera Capital sold 100,000 CoLucid Pharmaceuticals, Inc. shares in Q4 2016, an estimated $3.81M.
  • Nexthera Capital first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Nexthera Capital's CoLucid Pharmaceuticals, Inc. position peaked at $3.81M in Q3 2016.
  • 76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on Nexthera Capital's 13F filing for Q4 2016, filed 14 Feb 2017.